Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin

Gynecologic Oncology

Volumn 84, Issue 3, 2002, Pages 404-412

  Kolfschoten, G M ^a   Hulscher, T M ^a   Schrier, S M ^b   Van Houten, V M M ^a   Pinedo, H M ^a   Boven, E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Apoptosis; Bax, Bcl 2; Caspase 3; Cisplatin; Human ovarian cancer cell lines; p21 WAF1; p53

Indexed keywords

CASPASE 3; CISPLATIN; DNA FRAGMENT; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE; CELL NUCLEUS; CELL STRUCTURE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GIEMSA STAIN; HUMAN; HUMAN CELL; KINETICS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0036198430     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6537     Document Type: Article

References (45)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. Mechanisms of drug resistance in ovarian cancer
3. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
4. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy
5. Caspases: A decade of death research
6. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
7. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways
8. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma
9. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study
10. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: Correlation with histopathology and clinical features
11. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer
12. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
13. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
14. Mitochondria in chemotherapy-induced apoptosis: A prospective novel target of cancer therapy
15. Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis
16. Reversal of Adriamycin resistance by verapamil in human ovarian cancer
17. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice
18. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors
19. Identification of p53 gene mutations in bladder cancers and urine samples
20. Prevention of cycloheximide-induced apoptosis in hepatocytes by adenosine and by caspase inhibitors
21. DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status
22. Prediction of response to drug therapy of cancer - A review of in vitro assays
23. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53
24. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems
25. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53
26. Apoptosis as a measure of chemosensitivity to cisplatin and Taxol therapy in ovarian cancer cell lines
27. Biochemical determinants of apoptosis and necrosis
28. Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines
29. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair
30. Induction of WAF1/CIP1 by a p53-independent pathway
31. Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs
32. Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2
33. The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2
34. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma
35. BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
36. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line
37. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: Inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin
38. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin
39. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase
40. Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of ether death substrates in apoptosis
41. Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells
42. Induction of apoptosis in cisplatin-sensitive and -resistant human ovarian cancer cell lines
43. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines
44. Interdigital cell death can occur through a necrotic and caspase-independent pathway
45. Caspase-independent programmed cell death with necrotic morphology